Sound Income Strategies LLC Has $40,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Sound Income Strategies LLC increased its position in Becton, Dickinson and Company (NYSE:BDX) by 35.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 167 shares of the medical instruments supplier’s stock after buying an additional 44 shares during the quarter. Sound Income Strategies LLC’s holdings in Becton, Dickinson and Company were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Jennison Associates LLC increased its position in Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after acquiring an additional 18,786 shares during the period. Norden Group LLC raised its position in Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after purchasing an additional 49,559 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in Becton, Dickinson and Company during the 1st quarter worth about $11,998,000. Avity Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after buying an additional 5,527 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Becton, Dickinson and Company by 9.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock valued at $14,481,000 after buying an additional 5,006 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $240.02 on Tuesday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The company has a market cap of $69.37 billion, a PE ratio of 52.87, a P/E/G ratio of 1.79 and a beta of 0.42. The stock has a 50-day moving average of $236.46 and a 200-day moving average of $235.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the firm posted $2.96 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent analyst reports. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI increased their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.